Holen Sie sich die Stockscreener-App
6.125
0.91%
0.055
Schlusskurs vom Vortag:
$6.07
Offen:
$6.1
24-Stunden-Volumen:
8,757
Relative Volume:
0.17
Marktkapitalisierung:
$220.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.50M
KGV:
-7.9545
EPS:
-0.77
Netto-Cashflow:
$-30.10M
1W Leistung:
+2.51%
1M Leistung:
+15.24%
6M Leistung:
+102.48%
1J Leistung:
+155.21%
1-Tages-Spanne:
$6.0401
$6.30
1-Wochen-Bereich:
$5.7476
$6.30
52-Wochen-Spanne:
$2.20
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.125 | 307.12M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Strategies to average down on Eupraxia Pharmaceuticals Inc.Portfolio Gains Summary & Daily Chart Pattern Signals - newser.com
Applying chart zones and confluence areas to Eupraxia Pharmaceuticals Inc.Market Weekly Review & Daily Entry Point Alerts - newser.com
(EPRX) Comprehensive Trading Strategy Report (EPRX:CA) - news.stocktradersdaily.com
Trend Tracker for (EPRX.WT.A) - news.stocktradersdaily.com
Multi factor analysis applied to Eupraxia Pharmaceuticals Inc.Quarterly Profit Report & Reliable Trade Execution Plans - newser.com
Analysts Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Price Target at $11.00 - Defense World
Long term hold vs stop loss in Eupraxia Pharmaceuticals Inc.Trade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
Using fundamentals and technicals on Eupraxia Pharmaceuticals Inc.Quarterly Portfolio Review & Advanced Swing Trade Entry Plans - newser.com
(EPRX) Strategic Investment Guide (EPRX:CA) - news.stocktradersdaily.com
When is the best time to exit Eupraxia Pharmaceuticals Inc.Day Trade & Free Risk Controlled Daily Trade Plans - newser.com
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion - MSN
Can Eupraxia Pharmaceuticals Inc. stock double in next 5 years2025 Big Picture & Weekly High Return Opportunities - newser.com
Sentiment analysis tools applied to Eupraxia Pharmaceuticals Inc.July 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Using flow based indicators on Eupraxia Pharmaceuticals Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Is Eupraxia Pharmaceuticals Inc. (X43) stock considered safe havenEarnings Growth Summary & Consistent Return Strategy Ideas - newser.com
Can Eupraxia Pharmaceuticals Inc. (X43) stock attract analyst upgradesProfit Target & Trade Opportunity Analysis - newser.com
Detecting price anomalies in Eupraxia Pharmaceuticals Inc. with AIJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX) - MarketBeat
(EPRX) Trading Signals (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What is HC Wainwright’s Estimate for EPRX Q3 Earnings? - Defense World
Quantitative breakdown of Eupraxia Pharmaceuticals Inc. recent movePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Will Eupraxia Pharmaceuticals Inc. stock outperform Nasdaq indexEarnings Beat & High Accuracy Swing Trade Signals - newser.com
What is HC Wainwright's Estimate for EPRX Q3 Earnings? - MarketBeat
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - news.stocktradersdaily.com
Why Eupraxia Pharmaceuticals Inc. is moving today2025 Bull vs Bear & Verified Entry Point Detection - newser.com
Historical volatility pattern of Eupraxia Pharmaceuticals Inc. visualizedJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Measuring Eupraxia Pharmaceuticals Inc.’s beta against major indices2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Technical analysis overview for Eupraxia Pharmaceuticals Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
This small Canadian pharma stock is undervalued, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 2.5%What's Next? - MarketBeat
Why Eupraxia Pharmaceuticals Inc. (X43) stock could outperform next year2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Will Eupraxia Pharmaceuticals Inc. (X43) stock beat Nasdaq index returnsLayoff News & Real-Time Volume Surge Alerts - newser.com
What’s next for Eupraxia Pharmaceuticals Inc. stock price2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering - MSN
Raymond James Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Trend Tracker for (EPRX) (EPRX:CA) - news.stocktradersdaily.com
Craig-Hallum Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering - MSN
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study - Benzinga
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):